The Patent Finder

Valo Early Discovery, Inc.

11 patents currently held · Updated Nov 17, 2026
95 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Feb 2036
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 18, 2027
    The maintenance fee for Bicyclic [4,6,0] Hydroxamic Acids as Hdac Inhibitors (US 11,702,412) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
  • 2 fees due Feb 22 to 28, 2027 · next Feb 22
  • 1 fee due Aug 6, 2027
    The maintenance fee for 3-Alkyl-4-Amido-BICYCLIC [4,5,0] Hydroxamic Acids as Hdac Inhibitors (US 11,891,365) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
  • 1 fee due Sep 5, 2027
    The maintenance fee for Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors (US 11,919,839) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 11,274,0843-ARYL-4-Amido-BICYCLIC [4,5,0] Hydroxamic Acids as Hdac Inhibitors
In force
 · High confidence
In forceHigh confidence
US 11,274,0853-ARYL-BICYCLIC [4,5,0] Hydroxamic Acids as Hdac Inhibitors
In force
 · High confidence
In forceHigh confidence
US 11,279,6813-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
In force
 · High confidence
In forceHigh confidence
US 11,891,3653-Alkyl-4-Amido-BICYCLIC [4,5,0] Hydroxamic Acids as Hdac Inhibitors
In force
 · High confidence
In forceHigh confidence
US 11,739,071Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
In force
 · High confidence
In forceHigh confidence
US 12,018,030Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors
In force
 · High confidence
In forceHigh confidence
US 11,702,412Bicyclic [4,6,0] Hydroxamic Acids as Hdac Inhibitors
In force
 · High confidence
In forceHigh confidence
US 11,919,839Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 11,414,392[6,6] Fused Bicyclic HDAC8 Inhibitors
In force
 · High confidence
In forceHigh confidence
US 11,730,7212-Spiro-5- and 6-Hydroxamic Acid Indanes as Hdac Inhibitors
In force
 · High confidence
In forceHigh confidence
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
Also on record, not counted in the 11: 95 patents in force now held by others · 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 abandoned

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited